Parkinson Disease, IdiopathicMediPDNCT07838675
MediPD: An Online Mediterranean Diet Program for People Living With Parkinson's Disease
A study testing MediPD Online Mediterranean Diet Program in people with Parkinson Disease, Idiopathic, run by Queen's University, Belfast at 1 site in United Kingdom.
Trial summary
The aim of this pilot study is to assess whether an online Mediterranean diet programme called MediPD is acceptable and practical for people living with Parkinson's disease, and whether it can help them make and maintain changes towards a Mediterranean-style diet. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson Disease, Idiopathic
- What is being tested?
- MediPD Online Mediterranean Diet Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 10 Oct 2026to 29 Feb 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Self-reported idiopathic Parkinson's disease
- Age 18 years or older
- Community-dwelling and resident in the United Kingdom
- Access to an internet-enabled device and an active email address
- Mediterranean Diet Score ≤7/13, indicating low adherence to a Mediterranean diet
- Proficient in English
- Able to provide informed consent
Who cannot join
- Atypical or secondary parkinsonism
- Living in an institution
- Self-reported body mass index <18.5 kg/m²
- High risk of malnutrition, defined as MUST score ≥2
- Receiving prescribed nutritional support
- Significant cognitive impairment, defined as T-CogS ≤21
Show all 14Show fewer
- Pregnancy
- Active inflammatory bowel disease
- Dysphagia requiring a pureed diet
- Food allergies that would prevent adherence to a Mediterranean-style diet
- Following a vegan diet that would prevent adherence to the study's Mediterranean-style dietary intervention.
- Current participation in another interventional trial
- Participation in an investigational medicinal product trial within the previous 90 days where this may affect study outcomes or participant burden
- Previous participation in a My Moves Matter dietary programme.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Remote assessments from Centre for Public Health, Queens University Belfast
Belfast, BT12 6BA
Nicola Ann Ward, PhD, MSci, 07823368444, medipd@qub.ac.uk
Sinead O'Hagan, 07823368444, medipd@qub.ac.uk
About this study
Official title: Feasibility Of An Online Self-management Mediterranean Diet Program To Improve Dietary Behaviour And Quality Of Life For People Living With Parkinson's Disease: The MediPD Pilot Randomised Controlled Trial
The aim of this pilot study is to assess whether an online Mediterranean diet programme called MediPD is acceptable and practical for people living with Parkinson's disease, and whether it can help them make and maintain changes towards a Mediterranean-style diet.
The study will include 120 adults living in the United Kingdom with Parkinson's disease who have access to an internet-enabled device and currently have low adherence to a Mediterranean-style diet. Participants will be randomly assigned to one of two groups. One group will receive access to the MediPD online programme, which includes short educational videos, personalised dietary information, practical resources, goal-setting tools, and online dietetic support. The other group will continue with their usual care and will receive access to MediPD after completing the final study assessment.
Researchers will compare the groups to see whether MediPD improves adherence to a Mediterranean diet after 24 weeks. The study will also examine dietary intake, non-motor symptoms, quality of life, gastrointestinal symptoms, cognitive function, and how acceptable and practical the programme is to use. Assessments will take place at the start of the study, at 12 weeks, and at 24 weeks.
- Conditions
- Parkinson Disease, Idiopathic
- Being tested
- MediPD Online Mediterranean Diet Program
- Keywords
- Mediterranean Diet, Parkinson Disease, Digital Health, Online Intervention, Feasibility Study, Pilot Randomized Controlled Trial, Non-Motor Symptoms
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MediPD Online Mediterranean Diet ProgramBehavioural
MediPD is a 12-week online Mediterranean diet behaviour-change programme for people with Parkinson's disease. It provides personalised educational videos, practical resources, self-monitoring tools, and moderated dietetic support. Participants are encouraged to complete at least one module per week, aiming to adopt and maintain Mediterranean-style dietary changes over 24 weeks.
| Study group | Role | What they receive |
|---|---|---|
| MediPD Intervention | Experimental | Participants will receive access to the 12-week MediPD online Mediterranean diet behaviour-change program Receives: Behavioral: MediPD Online Mediterranean Diet Program |
| Wait-List Control | No intervention | Participants will continue to receive their usual care. After completing the final 24-week study assessment, participants in the wait-list control group will be offered access to the MediPD online program for 12 weeks. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 24 Weeks
Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet.
Measured: Baseline to 24 weeks
Secondary outcomes (6)
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 12 Weeks
Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet.
Measured: Baseline to 12 weeks
Change in self-reported dietary intake using a 24-hour Dietary Recall
Dietary intake will be assessed using Intake24, an online 24-hour dietary recall tool. Outcomes will include mean daily intake of energy (kcal/day), foods and macronutrients (g/day and, where appropriate, percentage of energy), and micronutrients (mg or µg/day, as appropriate). Higher values indicate greater intake of food/nutrients.
Measured: Baseline, 12 weeks and 24 weeks.
Change in Parkinson's Disease Non-Motor Symptoms using the Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
Non-motor symptoms will be assessed using the validated 52-item, rater-administered Movement Disorder Society Non-Motor Rating Scale (MDS-NMS). Total scores range from 0 to 832, with higher scores indicating a greater non-motor symptom burden and a worse outcome.
Measured: Baseline, 12 weeks and 24 weeks.
Change in reported Gastrointestinal Symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Gastrointestinal symptoms will be assessed using the 15-item Gastrointestinal Symptom Rating Scale (GSRS). Items are scored from 1 to 7 and summed to provide a total score ranging from 15 to 105. Higher total scores indicate greater gastrointestinal symptom severity and therefore a worse outcome.
Measured: Baseline, 12 weeks and 24 weeks.
Change in quality of life using the Parkinson's Disease Questionnaire (PDQ-39)
Quality of life will be assessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39), which covers eight domains. Each domain score is transformed to a 0-100 scale, and the mean of the eight domain scores provides the PDQ-39 Summary Index. Higher Summary Index scores indicate poorer health-related quality of life and therefore a worse outcome.
Measured: Baseline, 12 weeks and 24 weeks.
Change in cognitive function using TestMyBrain cognitive test battery
Cognitive function will be assessed using the TestMyBrain cognitive test battery, comprising Verbal Paired Associates, Visual Paired Associates, Backward Digit Span, Digit Symbol Matching, and Trail Making A and B. Each test score will be converted to a z-score and oriented so that higher scores consistently indicate better performance. The z-scores will be summed to provide an overall cognitive composite score with higher scores indicating better cognitive function.
Measured: Baseline, 12 weeks and 24 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2026
- Study start10 Oct 2026
- Primary completion30 Aug 2027 (estimated)
- Study completion29 Feb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson Disease, IdiopathicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Queen's University, Belfast
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Claire McEvoy, Queen's University, Belfast
- Investigators
- Claire T McEvoy, PhD, Mphil, RD, Principal investigator, Queens University Belfast
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07838675
- Sponsor's protocol ID
- 513675
- Acronym
- MediPD
- Status last verified
- Oct 2026
- First submitted
- 10 Sep 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Of An Online Self-management Mediterranean Diet Program To Improve Dietary Behaviour And Quality Of Life For People Living With Parkinson's Disease: The MediPD Pilot Randomised Controlled Trial
- ClinicalTrials.gov ID
- NCT07838675
- Acronym / sponsor ID
- MediPD / 513675
- Conditions
- Parkinson Disease, Idiopathic
- Keywords
- Mediterranean Diet, Parkinson Disease, Digital Health, Online Intervention, Feasibility Study, Pilot Randomized Controlled Trial, Non-Motor Symptoms
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Queen's University, BelfastUniversity, hospital or other
- Study start
- 10 Oct 2026 (actual)
- Primary completion
- 30 Aug 2027 (estimated)
- Study completion
- 29 Feb 2028 (estimated)
- First posted
- 24 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this pilot study is to assess whether an online Mediterranean diet programme called MediPD is acceptable and practical for people living with Parkinson's disease, and whether it can help them make and maintain changes towards a Mediterranean-style diet.
The study will include 120 adults living in the United Kingdom with Parkinson's disease who have access to an internet-enabled device and currently have low adherence to a Mediterranean-style diet. Participants will be randomly assigned to one of two groups. One group will receive access to the MediPD online programme, which includes short educational videos, personalised dietary information, practical resources, goal-setting tools, and online dietetic support. The other group will continue with their usual care and will receive access to MediPD after completing the final study assessment.
Researchers will compare the groups to see whether MediPD improves adherence to a Mediterranean diet after 24 weeks. The study will also examine dietary intake, non-motor symptoms, quality of life, gastrointestinal symptoms, cognitive function, and how acceptable and practical the programme is to use. Assessments will take place at the start of the study, at 12 weeks, and at 24 weeks.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MediPD Intervention | Experimental | Behavioral: MediPD Online Mediterranean Diet ProgramParticipants will receive access to the 12-week MediPD online Mediterranean diet behaviour-change program |
| Wait-List Control | No intervention | –Participants will continue to receive their usual care. After completing the final 24-week study assessment, participants in the wait-list control group will be offered access to the MediPD online program for 12 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Self-reported idiopathic Parkinson's disease
- Age 18 years or older
- Community-dwelling and resident in the United Kingdom
- Access to an internet-enabled device and an active email address
- Mediterranean Diet Score ≤7/13, indicating low adherence to a Mediterranean diet
Key exclusion criteria (14 listed)
- Atypical or secondary parkinsonism
- Living in an institution
- Self-reported body mass index <18.5 kg/m²
- High risk of malnutrition, defined as MUST score ≥2
- Receiving prescribed nutritional support
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MediPD Online Mediterranean Diet ProgramMediPD is a 12-week online Mediterranean diet behaviour-change programme for people with Parkinson's disease. It provides personalised educational videos, practical resources, self-monitoring tools, and moderated dietetic support. Participants are encouraged to complete at least one module per week, aiming to adopt and maintain Mediterranean-style dietary changes over 24 weeks. | Behavioural | MediPD Intervention |
Primary outcome
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 24 Weeks
Time frame: Baseline to 24 weeks
Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet.
6 secondary outcomes
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 12 Weeks
Time frame: Baseline to 12 weeks
Change in self-reported dietary intake using a 24-hour Dietary Recall
Time frame: Baseline, 12 weeks and 24 weeks.
Change in Parkinson's Disease Non-Motor Symptoms using the Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
Time frame: Baseline, 12 weeks and 24 weeks.
Change in reported Gastrointestinal Symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Time frame: Baseline, 12 weeks and 24 weeks.
Change in quality of life using the Parkinson's Disease Questionnaire (PDQ-39)
Time frame: Baseline, 12 weeks and 24 weeks.
Change in cognitive function using TestMyBrain cognitive test battery
Time frame: Baseline, 12 weeks and 24 weeks.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
Related trials for Parkinson Disease, Idiopathic
Not yet recruitingObservational study
Longitudinal Observation of Neurodegeneration in Parkinson's Disease Using Molecular Imaging and Blood Biomarkers
Idiopathic Parkinson Disease
Not yet recruiting
Non-invasive Vagus Nerve Stimulation for Parkinson's Disease
Idiopathic Parkinson Disease
RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson Disease, Parkinson
Recruiting
Ginger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease
REM Sleep Behavior Disorder, Parkinson s Disease
Recruiting
Video-oculography and Parkinson's Disease
Parkinson Disease, Idiopathic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Claire T McEvoy, PhD, Mphil, RD principal investigator
Queens University Belfast
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MediPD Online Mediterranean Diet Program in people with Parkinson Disease, Idiopathic, run by Queen's University, Belfast at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nicola A Ward, PhD, MSci (+44(0)7823368444, medipd@qub.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 24 Weeks (time frame: Baseline to 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.